chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Day 1-3 sore are w/ slight swelling. Took 2 Tylenol Day 1 and Day 2 plus iced my left arm both days. By Day 3 arm felt minimal sore, more back to normal. Reported all symptoms on V-safe.  Day 4 completely normal. Day 7- red circle around injection site with slight itching, No medication.  Communicated to medical director of rehab at my facility my delayed body response and reported on V-safe app. Day 8 exhausted slept 10 hours,  and body chills. no medication taken. Updated my director of rehab of symptoms. Tried to report on V-safe however app does not allow for reporting past Day 7. Day 9 continued exhaustion, had to leave work early. Head felt in a fog, unable to focus.  Day 10 all symptoms gone.
OBSTRUCTIVE SLEEP APNEA 4/5/2022 ACUTE NON ST ELEVATION MI ACUTE NON ST ELEVATION MI 4/12/2023 ACUTE NON ST ELEVATION MI OBSTRUCTIVE SLEEP APNEA 4/5/2022 ACUTE NON ST ELEVATION MI ACUTE NON ST ELEVATION MI 4/12/2023 ACUTE NON ST ELEVATION MI
No adverse event; Expired Moderna vaccine administered on 29Nov2022; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired Moderna vaccine administered on 29Nov2022) and NO ADVERSE EVENT (No adverse event) in a 26-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 061B22A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 01-Nov-2022, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 29-Nov-2022, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On 29-Nov-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired Moderna vaccine administered on 29Nov2022). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired Moderna vaccine administered on 29Nov2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Expired Moderna vaccine administered on 29Nov2022).    No concomitant medications were reported. Vial size was reported as 5.5 mL. The vial did not undergo any temperature excursions. No treatment details were reported.
3/29-81 year old female received the 1st dose of the Moderna COVID-19 vaccine at the center on 03/11/2021 @ 16:00. On 03/27/2021 morning pt started experiencing red rash, itchy, warm to touch, and swollen at the site of injection about 3 inches in diameter. Pt took hydrocortisone cream and that relieved the itching. Pt takes amlodipine, HCTZ, pantoprazole, celebrex, trazodone, fluticasone, and vitamins. Pt is diagnosed with hypertension and arthritis. Pt states allergies to aspirin, but it is only in the form of GI upset, and an allergy to albuterol in the form of a rapid heart beat, which is expected. Pt was advised to place warm compress on arm, take Tylenol, and if symptoms worsen or do not subside in 2 days to contact primary doctor to have arm examined. Consulted  and doctor was notified.
No adverse event; 16 patients were administered pediatric monovalent vaccines instead of bivalent boosters; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (16 patients were administered pediatric monovalent vaccines instead of bivalent boosters) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR6965B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 21-Dec-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 21-Dec-2022, the patient experienced WRONG PRODUCT ADMINISTERED (16 patients were administered pediatric monovalent vaccines instead of bivalent boosters). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (16 patients were administered pediatric monovalent vaccines instead of bivalent boosters) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (16 patients were administered pediatric monovalent vaccines instead of bivalent boosters).    This case contains information for the 2nd of 16 adult patients described by the reporter.  Concomitant Medication use information was not provided by reporter.  16 patients were administered pediatric monovalent vaccines instead of bivalent boosters on 21DEC2022.   Treatment Medication use information was not provided by reporter.   This case was linked to US-MODERNATX, INC.-MOD-2022-692175 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-692175:Master case
10/30/06 Vaccine administered at 10:05 am. at work. Patient developed a rash and was itchy approximately 20 minutes after vaccine administered.  Area of rash face, torso, hands, legs. RN examined her and recommended patient see her physician.  Patient saw her private physician at 12:20.  She reported difficulty breathing and MD did a nebulizer treatment.   On 10/31/06 she reported a fever of 102 On 11/1/06 patient returned to work and reported that she was achy and had a headache.
Approximately 8 hours after having vaccine woke at 10pm, sever muscle spasms all over, unable to walk, unable to stop large muscle group contractions, unable to talk, unable to talk, last about 2 hours in severe state. Unable to wale spouse next to me due to the severe nature could not move or talk.  Pain gradually reduced and spasms let up over next 4 hours. I did not see lol medical attention.
after received second dose, bruising; This is a spontaneous report from a contactable consumer or other non hcp (patient).  A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on an unspecified date as dose 2, single for covid-19 immunization. The patient medical history and concomitant medications were not reported. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot number was not reported) via an unspecified route of administration on an unspecified date as dose 1, single for covid-19 immunization. Patient stated she had received both doses of vaccine and after receiving the second dose experienced bruising on an unspecified date. Patient was calling on behalf of her sister who was unvaccinated and referenced "she heard being in contact" with those could impede menstrual cycle. Patient enquired about defining exposures during pregnancy, including through inhalation or skin contact and response included that there were no known risks of skin contact or inhalation exposure to the vaccine following routine administration of the vaccine during pregnancy or from inhaling the air from a vaccinated individual. Patient stated that she heard of children getting nosebleeds. Patient was asking cardiologist and indicated she bumped into something. The outcome of event was unknown.  No follow up attempts are needed; No further information is expected.
5-6 mins after injection c/o thick tongue, dizziness, hot feeling, nausea, numbness of chest that spontaneously resolved but recurred 10 mins later; no SOB, rash, itch. IMP: Impending anaphylactic/severe allergic reaction; pt given Benadryl 50mg/ml 1ml IM, Solumedrol 125 mg IM but no EPI since no SOB.
had fever 3 days p/vax;irritable & loss of appetite & very hyper for 3 wk;fever for 2 days 103;
10 minutes after pt received MMR and varicella vaccine she developed B/L swollen eyelids. No rash. No wheezing. Pt given dose of BENADRYL and PRELONE.
diarrhea; cramping; This is a spontaneous report from a contactable consumer (Patient). A 65-year-old female patient received second dose of BNT162B2(COVID-19 VACCINE, Solution for injection, Lot number& Expiry date not reported) via unspecified route of administration on unspecified date as second dose, single for COVID-19 Immunization. Patient medical history was not reported. Concomitant medication included secukinumab (COSENTYX) used for unspecified indication from unknown date and unknown if ongoing. Patient stated that she had diarrhea and cramping for the last 4 days after second Covid vaccine on unspecified date. The outcome of events was unknown.   Information on the lot/batch number has been requested.
This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administered  4 doses out of a 100 doses past the 30 day use by date), PRODUCT TEMPERATURE EXCURSION ISSUE (vial undergo temperature excursions), PRODUCT STORAGE ERROR (frozen storage / vials stored in freezer) and NO ADVERSE EVENT (No adverse event) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017B22A) for COVID-19 prophylaxis. No Medical History information was reported. On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 20-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 29-Jul-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 29-Jul-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (administered  4 doses out of a 100 doses past the 30 day use by date). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (vial undergo temperature excursions), PRODUCT STORAGE ERROR (frozen storage / vials stored in freezer) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (administered  4 doses out of a 100 doses past the 30 day use by date), PRODUCT TEMPERATURE EXCURSION ISSUE (vial undergo temperature excursions), PRODUCT STORAGE ERROR (frozen storage / vials stored in freezer) and NO ADVERSE EVENT (No adverse event) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (administered  4 doses out of a 100 doses past the 30 day use by date), PRODUCT TEMPERATURE EXCURSION ISSUE (vial undergo temperature excursions) and PRODUCT STORAGE ERROR (frozen storage / vials stored in freezer). No concomitant medication was reported. Patient did not have any allergies (medications, food and other products). The patient was never tested and diagnosed as COVID Positive. Patient did not have any medical history relating to mentioned AE and both Acute and Chronic illnesses at the time of vaccination. Reportedly, reporter had a temperature excursion from the day they received the vaccine on the 24-Jun-2022 until 24-Aug-2022, because their freezer was not acceptable according to the DOH, they did not know a what temperature the vials were because they did not have DDT. They had administer 4 doses out of a 100 doses. The vial was never stored in the refrigerator. Storage condition at the time of the excursion was frozen storage. One vial was punctured and discarded. No treatment information was provided.
2 of age got vaccinated, swelling of shoulder, (+) erythema, color (+), (+) pain, (+) tenderness.
Information has been received from a pharmacist concerning a female patient, who on 11-SEP-2012 was vaccinated with a dose of ZOSTAVAX (also reported PNEUMOVAX), dose and route not reported (lot # 0468AE - in validation, expiration date 04-APR-2013). It was reported that, in September 2012, the patient developed redness and swelling at the injection site as well as a headache. At the time of the report, the patient's outcome was unknown. Additional information is not expected.
dark red scars now; Itchy; red, raised spots along my waist and shoulder area; painful lump under TB injection area; TB injection scar swelled up; This spontaneous case was reported by a consumer and describes the occurrence of AXILLARY MASS (painful lump under TB injection area), SWELLING (TB injection scar swelled up), SCAR (dark red scars now), PRURITUS (Itchy) and RASH (red, raised spots along my waist and shoulder area) in a 22-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 038K20A and 039K20A) for COVID-19 vaccination.     The patient's past medical history included Chickenpox (Patient had chickenpox as a child.). Previously administered products included for an unreported indication: TUBERCULOSIS VACCINES (Patient received a tuberculosis vaccine as a child.). Concomitant products included AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL) for an unknown indication.   On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Feb-2021, the patient experienced AXILLARY MASS (painful lump under TB injection area) and SWELLING (TB injection scar swelled up). On 08-Feb-2021, the patient experienced PRURITUS (Itchy) and RASH (red, raised spots along my waist and shoulder area). On 08-Apr-2021, the patient experienced SCAR (dark red scars now). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) at a dose of 1 dosage form. On 05-Feb-2021, AXILLARY MASS (painful lump under TB injection area) and SWELLING (TB injection scar swelled up) had resolved. At the time of the report, SCAR (dark red scars now) had not resolved and PRURITUS (Itchy) and RASH (red, raised spots along my waist and shoulder area) had resolved.            Action taken with mRNA-1273 (Moderna COVID-19 Vaccine) in response to the event was not applicable.   This case was linked to MOD-2021-071135 (Patient Link).
Episode of varicella zoster in trigeminal distribution, complicated by kerato oveitis. Vesicle in various stages of development over nose, right side of forehead and temple.
Pt requested 2nd shingrix vaccine (hx of one prior received at this location). (System was down). Confirmed dose number with patient as being 2nd before administering. Upon logging into system later that evening, patient had previously received one dose before his first at this location, making this his third. Primary care provider notified, pt called and left VM. No notification of concern from patient over the weekend or today.
No adverse event; Patient received vaccine from pediatric vials instead of bivalent vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient received vaccine from pediatric vials instead of bivalent vaccine) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In October 2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In October 2022, the patient experienced WRONG PRODUCT ADMINISTERED (Patient received vaccine from pediatric vials instead of bivalent vaccine). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient received vaccine from pediatric vials instead of bivalent vaccine) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patient received vaccine from pediatric vials instead of bivalent vaccine).    No concomitant medications were reported.  The 26 adult patients received vaccine on 8-Oct-2022, 9-Oct-2022 and 10-Oct-2022, from pediatric vials of Moderna COVID-19 Vaccine instead of bivalent booster. The reporter was not aware of any adverse events after the vaccines were given.   No treatment medications were reported.  This case contains information for the 25 of 26 patients described by reporter.
After 4-5 months, joints and muscles aches became evident. Very stiff conditions, the doctor advised to take 400 units of Ibuprofen 3 times a day. Continues till this day. No other doses given due to problem.
pt recv vax JUL-AUG95 & 1mo later devel flushing, burning sensation, weakness myalgia, that reportedly still persists;pt reported severe h/a, tight muscles, face burning, legs burning, legs stiff & sore;numbness, tingling lt hand;rash
Per patient 2 days later arm, elbow, forearm, wrist became red swollen. Went to urgent care, been prescribed cephalexin for 10 days.
LEFT CERVICAL ADENOPATHY 1.5 CM LEFT AXILLARY ADENOPATHY 2CM
This spontaneous report was received from a female patient of unknown age reporting on herself. The patient's concurrent conditions included high blood pressure. No history of allergies were reported. On 20-OCT-2015, the patient was vaccinated with ZOSTAVAX (strength, frequency, lot number an expiration date not provided) in the left arm. Concomitant therapies included prednisone (manufacturer unknown), NEURONTIN, ZOVIRAX and TOPROL. In October 2015, a few days after receiving the vaccine, the patient experienced pain in extremity (reported as very sore), hypoaesthesia (reported as from the elbow to her wrist it was numb and tingly) and erythema (reported as was very bright red and warm). On an unspecified date, an nuclear magnetic resonance imaging (MRI) was performed to see if the numbness was coming from there but not results were provided. The patient sought for medical attention. She has been treated with many medications, but nothing was working. The patient stated she has been experiencing this for two months and still does not feel any better. The outcome of pain in extremity, hypoaesthesia and erythema was reported as not recovered/not resolved. At the time of this report, the relatedness between pain in extremity, hypoaesthesia and erythema and vaccination with ZOSTAVAX was unknown. No product quality complaint was involved. Additional information has been requested.
This morning the rash showed up on the back of arms and forehead.; Rash comes back on & off in different body parts after booster.Rash on both legs after booster.Rash is milder but still has them after booster.; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Rash comes back on & off in different body parts after booster.Rash on both legs after booster.Rash is milder but still has them after booster.) and RASH (This morning the rash showed up on the back of arms and forehead.) in a 52-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013F21A, 028A21A and 025A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Dec-2021, the patient experienced RASH (Rash comes back on & off in different body parts after booster.Rash on both legs after booster.Rash is milder but still has them after booster.). On 30-Dec-2021, the patient experienced RASH (This morning the rash showed up on the back of arms and forehead.). The patient was treated with FEXOFENADINE HYDROCHLORIDE (ALLEGRA [FEXOFENADINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency; DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency and FAMOTIDINE (PEPCID AC) for Adverse event, at an unspecified dose and frequency. At the time of the report, RASH (Rash comes back on & off in different body parts after booster.Rash on both legs after booster.Rash is milder but still has them after booster.) was resolving and RASH (This morning the rash showed up on the back of arms and forehead.) outcome was unknown.            No concomitant medication reported. It was reported that patient spoke to the doctor on the phone and the doctor instructed him to take Antihistamine.
I contracted COVID-19 on 06/07/2022 with symptoms of fever of 103, headache, body aches, and fatigue. I was improving in 3 days after initial onset when on the 5th day my symptoms returned and worsened. I developed with new symptoms of brain fog, cough, and diarrhea. I still have lingering symptoms of cough, fatigue, and brain fog which are recurring intermittently. I was prescribed Paxlovid on 06/14/2022.
Shake; Cold; Chills; This spontaneous case was reported by a consumer and describes the occurrence of TREMOR (Shake), NASOPHARYNGITIS (Cold) and CHILLS (Chills) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 044A21A and 015M20A) for COVID-19 vaccination.     The patient's past medical history included Hormone replacement therapy. Concurrent medical conditions included Blood pressure and Diabetes.   On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 11-Mar-2021, the patient experienced TREMOR (Shake), NASOPHARYNGITIS (Cold) and CHILLS (Chills). At the time of the report, TREMOR (Shake), NASOPHARYNGITIS (Cold) and CHILLS (Chills) outcome was unknown.            The patient is taking medicines for treatment of blood pressure, diabetes, and hormone replacement therapy. No treatment medication was reported.   Most recent FOLLOW-UP information incorporated above includes: On 30-Jun-2021: Follow-up was received and contains no significant information. On 27-Jul-2021: Follow-up was received and contains no new information.